Key result
A high rate of eGFR decline (≥10% per year) in hypertensive patients without baseline CKD was associated with a higher risk of cardiovascular events and death (HR 1.9; 95% CI 1.1-3.5; P=0.02).
Why the study?
It was unknown whether the rate and intensity of eGFR decline were associated with cardiovascular risk and death in hypertensive patients with a baseline eGFR above 60 ml/minute/1.73 m2.
Does a high rate of eGFR decline (≥10% per year) increase the risk of cardiovascular events and death in hypertensive patients without baseline chronic kidney disease?
Population
2,516 hypertensive patients with baseline eGFR >60 ml/minute/1.73 m2 and >=2 creatinine measurements
Comparison
eGFR reduction >=10% per year vs <10% per year
Design
Cohort study
Follow-up
4-year period
Authors
Loading...
Rapid eGFR decline may flag higher CV risk in non-CKD hypertension; hypothesis-generating for trajectory-based risk stratification.
Cohort (n=2,516)
Does a high rate of eGFR decline (≥10% per year) increase the risk of cardiovascular events and death in hypertensive patients without baseline chronic kidney disease?
Hazard Ratio: 1.9 (95% CI 1.1–3.5)
p-value: p=0.02
A rapid decline in eGFR (≥10% per year) identifies hypertensive patients without baseline CKD who are at significantly increased risk for cardiovascular events.
Tuero et al. (2019) conducted a cohort in Hypertension without chronic kidney disease (n=2,516). High rate of eGFR decline (≥10% per year) vs. Low rate of eGFR decline (<10% per year) was evaluated on Coronary artery disease, stroke, transitory ischemic accident, peripheral arterial disease, heart failure, atrial fibrillation, and death from any cause (HR 1.9, 95% CI 1.1-3.5, p=0.02). A high rate of eGFR decline (≥10% per year) in hypertensive patients without baseline CKD was associated with a higher risk of cardiovascular events and death (HR 1.9; 95% CI 1.1-3.5; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: